| Year |
Citation |
Score |
| 2023 |
Ranjan A, Thoenen EA, Kaida A, Wood S, Van Dyke T, Iwakuma T. Characterization of an Hypomorphic Allele in a Diethylnitrosamine-Induced Liver Carcinogenesis Model. Cancers. 15. PMID 37760565 DOI: 10.3390/cancers15184596 |
0.362 |
|
| 2022 |
Adhikari AS, Sullivan T, Bargaje R, Lu L, O'Sullivan TN, Song Y, Van Dyke T. Abrogation of Rb Tumor Suppression Initiates GBM in Differentiated Astrocytes by Driving a Progenitor Cell Program. Frontiers in Oncology. 12: 904479. PMID 35814428 DOI: 10.3389/fonc.2022.904479 |
0.331 |
|
| 2020 |
Shi M, Whorton AE, Sekulovski N, Paquet M, MacLean JA, Song Y, Van Dyke T, Hayashi K. Inactivation of TRP53, PTEN, RB1 and/or CDH1 in the ovarian surface epithelium induces ovarian cancer transformation and metastasis. Biology of Reproduction. PMID 31930396 DOI: 10.1093/biolre/ioaa008 |
0.372 |
|
| 2017 |
Song Y, Sullivan T, Klarmann K, Gilbert D, O'Sullivan TN, Lu L, Wang S, Haines DC, Van Dyke T, Keller JR. RB inactivation in keratin 18 positive thymic epithelial cells promotes non-cell autonomous T cell hyperproliferation in genetically engineered mice. Plos One. 12: e0171510. PMID 28158249 DOI: 10.1371/journal.pone.0171510 |
0.328 |
|
| 2015 |
El Meskini R, Iacovelli AJ, Kulaga A, Gumprecht M, Martin PL, Baran M, Householder DB, Van Dyke T, Weaver Ohler Z. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors. Disease Models & Mechanisms. 8: 45-56. PMID 25431423 DOI: 10.1242/dmm.018168 |
0.351 |
|
| 2014 |
Day CP, Carter J, Weaver Ohler Z, Bonomi C, El Meskini R, Martin P, Graff-Cherry C, Feigenbaum L, Tüting T, Van Dyke T, Hollingshead M, Merlino G. "Glowing head" mice: a genetic tool enabling reliable preclinical image-based evaluation of cancers in immunocompetent allografts. Plos One. 9: e109956. PMID 25369133 DOI: 10.1371/journal.pone.0109956 |
0.336 |
|
| 2014 |
Szabova L, Bupp S, Kamal M, Householder DB, Hernandez L, Schlomer JJ, Baran ML, Yi M, Stephens RM, Annunziata CM, Martin PL, Van Dyke TA, Weaver Ohler Z, Difilippantonio S. Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer. Plos One. 9: e95649. PMID 24748377 DOI: 10.1371/Journal.Pone.0095649 |
0.316 |
|
| 2014 |
Pérez de Castro I, Aguirre-Portolés C, Fernández-Miranda G, Cañamero M, Cowley DO, Van Dyke T, Malumbres M. Requirements for Aurora-A in tissue regeneration and tumor development in adult mammals. Cancer Research. 73: 6804-15. PMID 24242071 DOI: 10.1158/0008-5472.CAN-13-0586 |
0.391 |
|
| 2013 |
Song Y, Gilbert D, O'Sullivan TN, Yang C, Pan W, Fathalizadeh A, Lu L, Haines DC, Martin PL, Van Dyke T. Carcinoma initiation via RB tumor suppressor inactivation: a versatile approach to epithelial subtype-dependent cancer initiation in diverse tissues. Plos One. 8: e80459. PMID 24312475 DOI: 10.1371/Journal.Pone.0080459 |
0.356 |
|
| 2012 |
Yoon Y, Cowley DO, Gallant J, Jones SN, Van Dyke T, Rivera-Pérez JA. Conditional Aurora A deficiency differentially affects early mouse embryo patterning Developmental Biology. 371: 77-85. PMID 22939930 DOI: 10.1016/j.ydbio.2012.08.010 |
0.337 |
|
| 2012 |
Szabova L, Yin C, Bupp S, Guerin TM, Schlomer JJ, Householder DB, Baran ML, Yi M, Song Y, Sun W, McDunn JE, Martin PL, Van Dyke T, Difilippantonio S. Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Research. 72: 4141-53. PMID 22617326 DOI: 10.1158/0008-5472.Can-11-3834 |
0.382 |
|
| 2012 |
Serber DW, Rogala A, Makarem M, Rosson GB, Simin K, Godfrey V, Van Dyke T, Eaves CJ, Bultman SJ. The BRG1 chromatin remodeler protects against ovarian cysts, uterine tumors, and mammary tumors in a lineage-specific manner. Plos One. 7: e31346. PMID 22363625 DOI: 10.1371/Journal.Pone.0031346 |
0.437 |
|
| 2011 |
Cook DR, Solski PA, Bultman SJ, Kauselmann G, Schoor M, Kuehn R, Friedman LS, Cowley DO, Van Dyke T, Yeh JJ, Johnson L, Der CJ. The ect2 rho Guanine nucleotide exchange factor is essential for early mouse development and normal cell cytokinesis and migration. Genes & Cancer. 2: 932-42. PMID 22701760 DOI: 10.1177/1947601912437035 |
0.402 |
|
| 2011 |
Lu X, Yang C, Yin C, Van Dyke T, Simin K. Apoptosis is the essential target of selective pressure against p53, whereas loss of additional p53 functions facilitates carcinoma progression. Molecular Cancer Research : McR. 9: 430-9. PMID 21385880 DOI: 10.1158/1541-7786.Mcr-10-0277 |
0.6 |
|
| 2010 |
Walrath JC, Hawes JJ, Van Dyke T, Reilly KM. Genetically engineered mouse models in cancer research. Advances in Cancer Research. 106: 113-64. PMID 20399958 DOI: 10.1016/S0065-230X(10)06004-5 |
0.316 |
|
| 2010 |
Chen S, Sanford CA, Sun J, Choi V, Van Dyke T, Samulski RJ, Rathmell WK. VHL and PTEN loss coordinate to promote mouse liver vascular lesions. Angiogenesis. 13: 59-69. PMID 20221685 DOI: 10.1007/S10456-010-9164-2 |
0.3 |
|
| 2009 |
DelBove J, Kuwahara Y, Mora-Blanco EL, Godfrey V, Funkhouser WK, Fletcher CD, Van Dyke T, Roberts CW, Weissman BE. Inactivation of SNF5 cooperates with p53 loss to accelerate tumor formation in Snf5(+/-);p53(+/-) mice. Molecular Carcinogenesis. 48: 1139-48. PMID 19676100 DOI: 10.1002/Mc.20568 |
0.454 |
|
| 2009 |
Schliekelman M, Cowley DO, O'Quinn R, Oliver TG, Lu C, Salmon ED, Van Dyke T. Impaired Bub1 function in vivo compromises tension-dependent checkpoint function leading to aneuploidy and tumorigenesis Cancer Research. 69: 45-54. PMID 19117986 DOI: 10.1158/0008-5472.Can-07-6330 |
0.666 |
|
| 2009 |
Cowley DO, Rivera-Pérez JA, Schliekelman M, He YJ, Oliver TG, Lu C, O'Quinn R, Salmon ED, Magnuson T, Van Dyke T. Aurora-a kinase is essential for bipolar spindle formation and early development Molecular and Cellular Biology. 29: 1059-1071. PMID 19075002 DOI: 10.1128/Mcb.01062-08 |
0.683 |
|
| 2008 |
Lu X, Yang C, Hill R, Yin C, Hollander MC, Fornace AJ, Van Dyke T. Inactivation of gadd45a sensitizes epithelial cancer cells to ionizing radiation in vivo resulting in prolonged survival Cancer Research. 68: 3579-3583. PMID 18483238 DOI: 10.1158/0008-5472.Can-07-5533 |
0.663 |
|
| 2007 |
Chai J, Lu X, Godfrey V, Fletcher C, Roberts CW, Van Dyke T, Weissman BE. Tumor-specific cooperation of retinoblastoma protein family and Snf5 inactivation. Cancer Research. 67: 3002-9. PMID 17409406 DOI: 10.1158/0008-5472.Can-06-4207 |
0.605 |
|
| 2006 |
McLear JA, Garcia-Fresco G, Bhat MA, Van Dyke TA. In vivo inactivation of pRb, p107 and p130 in murine neuroprogenitor cells leads to major CNS developmental defects and high seizure rates. Molecular and Cellular Neurosciences. 33: 260-73. PMID 16979903 DOI: 10.1016/J.Mcn.2006.07.012 |
0.63 |
|
| 2005 |
Hill R, Song Y, Cardiff RD, Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell. 123: 1001-11. PMID 16360031 DOI: 10.1016/J.Cell.2005.09.030 |
0.638 |
|
| 2005 |
Hill R, Song Y, Cardiff RD, Van Dyke T. Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model. Cancer Research. 65: 10243-54. PMID 16288012 DOI: 10.1158/0008-5472.Can-05-1579 |
0.59 |
|
| 2005 |
Cowley DO, Muse GW, Van Dyke T. A dominant interfering Bub1 mutant is insufficient to induce or alter thymic tumorigenesis in vivo, even in a sensitized genetic background. Molecular and Cellular Biology. 25: 7796-802. PMID 16107724 DOI: 10.1128/MCB.25.17.7796-7802.2005 |
0.484 |
|
| 2005 |
Xiao A, Yin C, Yang C, Di Cristofano A, Pandolfi PP, Van Dyke T. Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation. Cancer Research. 65: 5172-80. PMID 15958561 DOI: 10.1158/0008-5472.Can-04-3902 |
0.458 |
|
| 2005 |
Nistér M, Tang M, Zhang XQ, Yin C, Beeche M, Hu X, Enblad G, van Dyke T, Wahl GM. p53 must be competent for transcriptional regulation to suppress tumor formation. Oncogene. 24: 3563-73. PMID 15750633 DOI: 10.1038/Sj.Onc.1208354 |
0.393 |
|
| 2004 |
Albright CD, Salganik RI, Van Dyke T. Dietary depletion of vitamin E and vitamin A inhibits mammary tumor growth and metastasis in transgenic mice. The Journal of Nutrition. 134: 1139-44. PMID 15113960 DOI: 10.1093/jn/134.5.1139 |
0.321 |
|
| 2004 |
Simin K, Wu H, Lu L, Pinkel D, Albertson D, Cardiff RD, Van Dyke T. pRb inactivation in mammary cells reveals common mechanisms for tumor initiation and progression in divergent epithelia. Plos Biology. 2: E22. PMID 14966529 DOI: 10.1371/journal.pbio.0020022 |
0.485 |
|
| 2003 |
Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, Cordon-Cardo C, Pandolfi PP. Pten dose dictates cancer progression in the prostate. Plos Biology. 1: E59. PMID 14691534 DOI: 10.1371/Journal.Pbio.0000059 |
0.301 |
|
| 2002 |
Weiss WA, Israel M, Cobbs C, Holland E, James CD, Louis DN, Marks C, McClatchey AI, Roberts T, Van Dyke T, Wetmore C, Chiu IM, Giovannini M, Guha A, Higgins RJ, et al. Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene. 21: 7453-63. PMID 12386807 DOI: 10.1038/Sj.Onc.1205936 |
0.302 |
|
| 2002 |
Xiao A, Wu H, Pandolfi PP, Louis DN, Van Dyke T. Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell. 1: 157-68. PMID 12086874 DOI: 10.1016/S1535-6108(02)00029-6 |
0.389 |
|
| 2002 |
Tolbert D, Lu X, Yin C, Tantama M, Van Dyke T. p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo. Molecular and Cellular Biology. 22: 370-7. PMID 11739748 DOI: 10.1128/Mcb.22.1.370-377.2002 |
0.607 |
|
| 2000 |
Salganik RI, Albright CD, Rodgers J, Kim J, Zeisel SH, Sivashinskiy MS, Van Dyke TA. Dietary antioxidant depletion: enhancement of tumor apoptosis and inhibition of brain tumor growth in transgenic mice. Carcinogenesis. 21: 909-14. PMID 10783311 |
0.309 |
|
| 1994 |
Van Dyke TA. Analysis of viral-host protein interactions and tumorigenesis in transgenic mice Seminars in Cancer Biology. 5: 47-60. PMID 8186388 |
0.391 |
|
| 1987 |
van Dyke TA, Finlay C, Miller D, Marks J, Lozano G, Levine AJ. Relationship between simian virus 40 large tumor antigen expression and tumor formation in transgenic mice Journal of Virology. 61: 2029-2032. PMID 3033329 DOI: 10.1128/Jvi.61.6.2029-2032.1987 |
0.338 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2008 |
Reilly KM, Van Dyke T. It takes a (dysfunctional) village to raise a tumor. Cell. 135: 408-10. PMID 18984150 DOI: 10.1016/J.Cell.2008.10.009 |
0.297 |
|
| 2007 |
Van Dyke T. p53 and tumor suppression. The New England Journal of Medicine. 356: 79-81. PMID 17202460 DOI: 10.1056/NEJMcibr066301 |
0.295 |
|
| 2013 |
Vitucci M, Karpinich NO, Bash RE, Werneke AM, Schmid RS, White KK, McNeill RS, Huff B, Wang S, Van Dyke T, Miller CR. Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis. Neuro-Oncology. 15: 1317-29. PMID 23814263 DOI: 10.1093/Neuonc/Not084 |
0.276 |
|
| 2005 |
Brubaker LM, Bullitt E, Yin C, Van Dyke T, Lin W. Magnetic resonance angiography visualization of abnormal tumor vasculature in genetically engineered mice. Cancer Research. 65: 8218-23. PMID 16166297 DOI: 10.1158/0008-5472.Can-04-4355 |
0.265 |
|
| 2007 |
Johnson CE, Huang YY, Parrish AB, Smith MI, Vaughn AE, Zhang Q, Wright KM, Van Dyke T, Wechsler-Reya RJ, Kornbluth S, Deshmukh M. Differential Apaf-1 levels allow cytochrome c to induce apoptosis in brain tumors but not in normal neural tissues. Proceedings of the National Academy of Sciences of the United States of America. 104: 20820-5. PMID 18093951 DOI: 10.1073/Pnas.0709101105 |
0.262 |
|
| 1990 |
Yan C, Costa RH, Darnell JE, Chen JD, Van Dyke TA. Distinct positive and negative elements control the limited hepatocyte and choroid plexus expression of transthyretin in transgenic mice. The Embo Journal. 9: 869-78. PMID 1690125 |
0.258 |
|
| 2007 |
Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, ... ... Van Dyke T, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biology. 8: R76. PMID 17493263 DOI: 10.1186/Gb-2007-8-5-R76 |
0.254 |
|
| 2015 |
Chen J, Hackett CS, Zhang S, Song YK, Bell RJ, Molinaro AM, Quigley DA, Balmain A, Song JS, Costello JF, Gustafson WC, Van Dyke T, Kwok PY, Khan J, Weiss WA. The genetics of splicing in neuroblastoma. Cancer Discovery. 5: 380-95. PMID 25637275 DOI: 10.1158/2159-8290.Cd-14-0892 |
0.253 |
|
| 2013 |
Song Y, Zhang Q, Kutlu B, Difilippantonio S, Bash R, Gilbert D, Yin C, O'Sullivan TN, Yang C, Kozlov S, Bullitt E, McCarthy KD, Kafri T, Louis DN, Miller CR, ... ... Van Dyke T, et al. Evolutionary etiology of high-grade astrocytomas. Proceedings of the National Academy of Sciences of the United States of America. 110: 17933-8. PMID 24114272 DOI: 10.1073/Pnas.1317026110 |
0.25 |
|
| 2006 |
Gutmann DH, Maher EA, Van Dyke T. Mouse models of human cancers consortium workshop on nervous system tumors Cancer Research. 66: 10-13. PMID 16397207 DOI: 10.1158/0008-5472.Can-05-3180 |
0.249 |
|
| 1997 |
Patrick TA, Kranz DM, van Dyke TA, Roy EJ. Folate receptors as potential therapeutic targets in choroid plexus tumors of SV40 transgenic mice. Journal of Neuro-Oncology. 32: 111-23. PMID 9120540 DOI: 10.1023/A:1005713115147 |
0.249 |
|
| 2017 |
Yu F, Jiang Y, Lu L, Cao M, Qiao Y, Liu X, Liu D, Van Dyke T, Wang F, Yao X, Guo J, Yang Z. Aurora-A promotes the establishment of spindle assembly checkpoint by priming the Haspin-Aurora-B feedback loop in late G2 phase. Cell Discovery. 3: 16049. PMID 28101375 DOI: 10.1038/Celldisc.2016.49 |
0.23 |
|
| 2014 |
Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 159: 80-93. PMID 25259922 DOI: 10.1016/J.Cell.2014.08.007 |
0.229 |
|
| 2020 |
Pérez-Guijarro E, Yang HH, Araya RE, El Meskini R, Michael HT, Vodnala SK, Marie KL, Smith C, Chin S, Lam KC, Thorkelsson A, Iacovelli AJ, Kulaga A, Fon A, Michalowski AM, ... ... Van Dyke T, et al. Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy. Nature Medicine. PMID 32284588 DOI: 10.1038/S41591-020-0818-3 |
0.229 |
|
| 2010 |
Van Dyke T. Finding the tumor copycat: approximating a human cancer. Nature Medicine. 16: 976-7. PMID 20823881 DOI: 10.1038/nm0910-976 |
0.222 |
|
| 2002 |
Perkins EJ, Nair A, Cowley DO, Van Dyke T, Chang Y, Ramsden DA. Sensing of intermediates in V(D)J recombination by ATM. Genes & Development. 16: 159-64. PMID 11799059 DOI: 10.1101/Gad.956902 |
0.214 |
|
| 2014 |
Hackett CS, Quigley DA, Wong RA, Chen J, Cheng C, Song YK, Wei JS, Pawlikowska L, Bao Y, Goldenberg DD, Nguyen K, Gustafson WC, Rallapalli SK, Cho YJ, Cook JM, ... ... Van Dyke T, et al. Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma. Cell Reports. 9: 1034-46. PMID 25437558 DOI: 10.1016/J.Celrep.2014.09.046 |
0.214 |
|
| 2021 |
El Meskini R, Atkinson D, Kulaga A, Abdelmaksoud A, Gumprecht M, Pate N, Hayes S, Oberst M, Kaplan IM, Raber P, Van Dyke T, Sharan SK, Hollingsworth R, Day CP, Merlino G, et al. Distinct biomarker profiles and TCR sequence diversity characterize the response to PD-L1 blockade in a mouse melanoma model. Molecular Cancer Research : McR. PMID 33888600 DOI: 10.1158/1541-7786.MCR-20-0881 |
0.212 |
|
| 1990 |
Costa RH, Van Dyke TA, Yan C, Kuo F, Darnell JE. Similarities in transthyretin gene expression and differences in transcription factors: liver and yolk sac compared to choroid plexus. Proceedings of the National Academy of Sciences of the United States of America. 87: 6589-93. PMID 2395861 |
0.206 |
|
| 2012 |
Weaver Z, Difilippantonio S, Carretero J, Martin PL, El Meskini R, Iacovelli AJ, Gumprecht M, Kulaga A, Guerin T, Schlomer J, Baran M, Kozlov S, McCann T, Mena S, Al-Shahrour F, ... ... Van Dyke T, et al. Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response. Cancer Research. 72: 5921-33. PMID 22969147 DOI: 10.1158/0008-5472.CAN-12-0736 |
0.206 |
|
| 2014 |
Dan HC, Ebbs A, Pasparakis M, Van Dyke T, Basseres DS, Baldwin AS. Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of rapamycin) by IκB kinase α (IKKα). The Journal of Biological Chemistry. 289: 25227-40. PMID 24990947 DOI: 10.1074/Jbc.M114.554881 |
0.201 |
|
| 1991 |
Brosnan MJ, Chen LH, Wheeler CE, Van Dyke TA, Koretsky AP. Phosphocreatine protects ATP from a fructose load in transgenic mouse liver expressing creatine kinase. The American Journal of Physiology. 260: C1191-200. PMID 2058653 DOI: 10.1152/Ajpcell.1991.260.6.C1191 |
0.197 |
|
| 2013 |
Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, Sheets M, St Martin T, Karp R, van Kalken D, Chaturvedi P, ... ... Van Dyke T, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discovery. 3: 1404-15. PMID 24065731 DOI: 10.1158/2159-8290.Cd-13-0314 |
0.191 |
|
| 2013 |
Merlino G, Flaherty K, Acquavella N, Day CP, Aplin A, Holmen S, Topalian S, Van Dyke T, Herlyn M. Meeting report: The future of preclinical mouse models in melanoma treatment is now. Pigment Cell & Melanoma Research. 26: E8-E14. PMID 23531109 DOI: 10.1111/Pcmr.12099 |
0.191 |
|
| 2008 |
Li W, Asokan A, Wu Z, Van Dyke T, DiPrimio N, Johnson JS, Govindaswamy L, Agbandje-McKenna M, Leichtle S, Eugene Redmond D, McCown TJ, Petermann KB, Sharpless NE, Samulski RJ. Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1252-1260. PMID 28178482 DOI: 10.1038/Mt.2008.100 |
0.186 |
|
| 2008 |
Li W, Asokan A, Wu Z, Van Dyke T, DiPrimio N, Johnson JS, Govindaswamy L, Agbandje-McKenna M, Leichtle S, Redmond DE, McCown TJ, Petermann KB, Sharpless NE, Samulski RJ. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1252-60. PMID 18500254 DOI: 10.1038/mt.2008.100 |
0.186 |
|
| 2015 |
Day CP, Merlino G, Van Dyke T. Preclinical mouse cancer models: a maze of opportunities and challenges. Cell. 163: 39-53. PMID 26406370 DOI: 10.1016/j.cell.2015.08.068 |
0.18 |
|
| 2002 |
Van Dyke T, Jacks T. Cancer modeling in the modern era: progress and challenges. Cell. 108: 135-44. PMID 11832204 DOI: 10.1016/S0092-8674(02)00621-9 |
0.173 |
|
| 2005 |
Li C, Bowles DE, Van Dyke T, Samulski RJ. Adeno-associated virus vectors: Potential applications for cancer gene therapy Cancer Gene Therapy. 12: 913-925. PMID 15962012 DOI: 10.1038/Sj.Cgt.7700876 |
0.171 |
|
| 2008 |
Wu Z, Sun J, Zhang T, Yin C, Yin F, Van Dyke T, Samulski RJ, Monahan PE. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 280-9. PMID 18059373 DOI: 10.1038/Sj.Mt.6300355 |
0.154 |
|
| 2016 |
Thomas RM, Van Dyke T, Merlino G, Day CP. Concepts in Cancer Modeling: A Brief History. Cancer Research. PMID 27694601 DOI: 10.1158/0008-5472.CAN-16-1293 |
0.119 |
|
| 2002 |
Amador-Zarco JJ, Mora-Tiscareño A, Sangri-Pinto AG, Braun-Roth G, Dressler LG, Kulwichit W, Van Dyke T, Calderón-Garcidueñas L. Nasal squamous cell carcinoma in a child. The Journal of Otolaryngology. 31: 45-9. PMID 11881772 DOI: 10.2310/7070.2002.19327 |
0.117 |
|
| 1990 |
Brosnan MJ, Chen L, Van Dyke TA, Koretsky AP. Free ADP levels in transgenic mouse liver expressing creatine kinase. Effects of enzyme activity, phosphagen type, and substrate concentration. The Journal of Biological Chemistry. 265: 20849-55. PMID 2249991 |
0.116 |
|
| 2007 |
Der CJ, Van Dyke T. Stopping ras in its tracks. Cell. 129: 855-7. PMID 17540164 DOI: 10.1016/J.Cell.2007.05.031 |
0.114 |
|
| 2005 |
Van Dyke T. Cancer biology: sense out of missense. Nature. 434: 287-8. PMID 15772635 DOI: 10.1038/434287a |
0.104 |
|
| 1980 |
Van Dyke TA, Flanegan JB. Identification of poliovirus polyupeptide P63 as a soluble RNA-dependent RNA polymerase Journal of Virology. 35: 732-740. PMID 6252335 DOI: 10.1128/jvi.35.3.732-740.1980 |
0.102 |
|
| 2009 |
Kuslak SL, Van Dyke T. Advances in Prostate Cancer Research--AACR Special Conference In Cancer Research. Idrugs : the Investigational Drugs Journal. 12: 159-62. PMID 19333894 |
0.1 |
|
| 2021 |
Pérez-Guijarro E, Yang HH, Araya RE, El Meskini R, Michael HT, Vodnala SK, Marie KL, Smith C, Chin S, Lam KC, Thorkelsson A, Iacovelli AJ, Kulaga A, Fon A, Michalowski AM, ... ... Van Dyke T, et al. Author Correction: Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy. Nature Medicine. PMID 33514948 DOI: 10.1038/s41591-021-01252-6 |
0.075 |
|
| 2012 |
Van Dyke T, Merlino G. β-catenin in metastatic melanoma--the smoking gun reloaded. Pigment Cell & Melanoma Research. 25: 125-6. PMID 22409365 DOI: 10.1111/j.1755-148X.2011.00964.x |
0.036 |
|
| 1979 |
Flanegan JB, Van Dyke TA. Isolation of a soluble and template-dependent poliovirus RNA polymerase that copies virion RNA in vitro Journal of Virology. 32: 155-161. PMID 232168 DOI: 10.1128/jvi.32.1.155-161.1979 |
0.033 |
|
| 1982 |
Van Dyke TA, Rickles RJ, Flanegan JB. Genome-length copies of poliovirion RNA are synthesized in vitro by the poliovirus RNA-dependent RNA polymerase Journal of Biological Chemistry. 257: 4610-4617. PMID 6279640 |
0.016 |
|
| Hide low-probability matches. |